SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its mainnet launch and institutional validation, including its Coinbase 50 index inclusion, drive bullish conviction in its utility and long-term potential, yet the community remains sharply divided amid persistent price drops leading to strong skepticism about the project's viability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx is trending as Gilead Sciences announced its acquisition for $7.8 billion, with the community focusing on the substantial premium and the strategic value of Arcellx's promising CAR T-cell therapy, anito-cel, which has shown strong clinical data for multiple myeloma.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA granting Priority Review for AXS-05 in Alzheimer's disease agitation, setting an April PDUFA date, alongside robust Q4 earnings and strong commercial growth for its CNS therapies. The community is highly optimistic about AXS-05's market potential and the company's trajectory towards cash flow positivity, further supported by multiple analyst upgrades and pipeline advancements.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is actively discussed following its recent financial results, which showed solid U.S. same-store sales growth and a 15% dividend increase, alongside reports of prominent hedge funds, including Warren Buffett's Berkshire Hathaway, increasing their positions. The community is debating if its "Hungry for MORE" strategy and market leadership can continue to drive growth amidst a mixed restaurant sector and concerns over valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MediaCos EstrellaTV Rewrites History with Record-Breaking Prime Time Growth, Leading All Broadcast Networks in 2025

MediaCo Holding Inc. (Nasdaq: MDIA) today announced that its flagship Spanish-language network, EstrellaTV, has achieved its largest annual Year-over-Year (YoY) P18-49 prime time percentage growth in...

MediaCos EstrellaTV Extends Breakout Momentum to Start 2026, Delivering Category-Leading Prime Time Growth

EstrellaTV, a division of MediaCo Holding Inc. (Nasdaq: MDIA), opened 2026 with decisive momentum, closing January with its fourth consecutive month of year-over-year prime time growth among Adults...

MediaCo Holding Inc. (NASDAQ:MDIA) Short Interest Up 50.8% in January

MediaCo Holding Inc. (NASDAQ:MDIA - Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 56,386 shares, an...

MediaCo Appoints Maire Mason to Lead Local Radio and Television Operations, Driving Major New York Market Shift

MediaCo Holding Inc. (Nasdaq: MDIA) today announced the appointment of Maire Mason as Vice President and General Manager of Local MediaCo Markets, marking a significant leadership move in the New...

MediaCos EstrellaTV to Televise and Stream Tigres and FC Jurez Home Matches Throughout Liga MX Clausura 2026

EstrellaTV, the multiplatform Spanish-language network owned by MediaCo Holding Inc. (Nasdaq: MDIA), today announced comprehensive coverage of Tigres, Tigres Femenil, FC Jurez and FC Jurez Femenil...

MediaCo Posts Breakout End-of-Year Audio Growth, Ranking Among the Fastest-Growing Radio Broadcasters in America

MediaCo Holding Inc. (Nasdaq: MDIA) today announced strong year-end audience growth across its radio portfolio, delivering significant gains in key markets and reinforcing its position as one of the...

MediaCos EstrellaTV Announces the Launch of New Orlando Television Station, Expanding Presence in One of the Nations Fastest-Growing Hispanic Markets

MediaCo Holding Inc. (Nasdaq: MDIA) announced that EstrellaTV will launch television station WDYB-CD in Orlando, Florida, significantly strengthening the networks footprint in one of the nations...

MediaCo Announces Historic Audience Growth for EstrellaTV in 2025

MediaCo Holding Inc. (Nasdaq: MDIA) today announced that EstrellaTV delivered historic audience growth in 2025, marking a major inflection point for the network and its strongest performance in more...

Sigma and MediaCo Launch Audio Network Targeting 150 Million Multicultural Population Nationwide

MediaCo Holding Inc. (Nasdaq: MDIA) today announced the launch of Sigma Audio Networks LLC, a groundbreaking multicultural audio network with a bold mission: to fundamentally modernize how...

MediaCo Holding Inc. (NASDAQ:MDIA) Short Interest Update

MediaCo Holding Inc. (NASDAQ:MDIA - Get Free Report) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 37,396 shares, a...

Mediaco Holding, Inc. is a radio broadcasting media company. Its purpose is to acquire and operates radio stations and its associated assets located in New York. The firm operates through Radio and Outdoor Advertising segments. The company was founded in June 2019 and is headquartered in Indianapolis, IN.

Current Price	$0.603
Prev Close	$0.60
Open	$0.5792
Dividend Yield	0.00%
50-Day Moving Average	$0.6464
Beta	0.47
Avg. Volume	149,176.15
PE Ratio	-1.06

52-Week High	$1.60
52-Week Low	$0.538
Market Capitalization	$49.35M
EPS (Annual)	-$0.0824
Price to Book	0.57
Revenue Per Employee	$234,818.18

MDIA
MediaCo Holding Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Fundamentals

Info

Latest MDIA News

MDIAMediaCo Holding Inc - Ordinary Shares - Class A